Patient preferences in retinal drug delivery

Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brandon Jacobs, Nicholas Palmer, Trupti Shetty, Helen Dimaras, Amir Hajrasouliha, Denis Jusufbegovic, Timothy W. Corson
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:eeb3a47168d044c68bc3bc7eb9108ec8
record_format dspace
spelling oai:doaj.org-article:eeb3a47168d044c68bc3bc7eb9108ec82021-12-02T18:14:00ZPatient preferences in retinal drug delivery10.1038/s41598-021-98568-72045-2322https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec82021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98568-7https://doaj.org/toc/2045-2322Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with IVT injections to establish factors influencing low compliance rates while gauging treatment delivery method preferences. Demographics, perspectives, and treatment preferences were collected via IRB-approved, self-administered survey sent to Glick Eye Institute patients treated via IVT injections. Demographics, diagnoses, and treatments were ascertained from respondents’ medical records. Gender, age, and number of IVT injections received were used as stratifications. Five-level Likert-style scales and t-tests evaluated responses and stratification comparisons. The most common diagnoses in the respondent population (n = 54; response rate = 5%) were age-related macular degeneration, macular edema, and diabetic retinopathy. Respondents had varying levels of education, income, and age. Most (83%) admitted feeling anxious prior to their first IVT injection, but 80% reported willingness to receive IVT injections indefinitely, with a preference for ophthalmologist visits every 1–3 months. Eye drops would be preferred over IVT injections by 76% of respondents, while 65% preferred oral tablets, due to several perceived negative factors of IVT injections and positive factors for eye drops. Stratified groups did not differ in responses to survey questions. RVD patients will accept IVT injections for vision preservation, but alternative delivery methods like eye drops or oral tablets would be preferred. Thus, development of eye drop and oral therapeutics for RVD treatment is further emphasized by these findings.Brandon JacobsNicholas PalmerTrupti ShettyHelen DimarasAmir HajrasoulihaDenis JusufbegovicTimothy W. CorsonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Brandon Jacobs
Nicholas Palmer
Trupti Shetty
Helen Dimaras
Amir Hajrasouliha
Denis Jusufbegovic
Timothy W. Corson
Patient preferences in retinal drug delivery
description Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with IVT injections to establish factors influencing low compliance rates while gauging treatment delivery method preferences. Demographics, perspectives, and treatment preferences were collected via IRB-approved, self-administered survey sent to Glick Eye Institute patients treated via IVT injections. Demographics, diagnoses, and treatments were ascertained from respondents’ medical records. Gender, age, and number of IVT injections received were used as stratifications. Five-level Likert-style scales and t-tests evaluated responses and stratification comparisons. The most common diagnoses in the respondent population (n = 54; response rate = 5%) were age-related macular degeneration, macular edema, and diabetic retinopathy. Respondents had varying levels of education, income, and age. Most (83%) admitted feeling anxious prior to their first IVT injection, but 80% reported willingness to receive IVT injections indefinitely, with a preference for ophthalmologist visits every 1–3 months. Eye drops would be preferred over IVT injections by 76% of respondents, while 65% preferred oral tablets, due to several perceived negative factors of IVT injections and positive factors for eye drops. Stratified groups did not differ in responses to survey questions. RVD patients will accept IVT injections for vision preservation, but alternative delivery methods like eye drops or oral tablets would be preferred. Thus, development of eye drop and oral therapeutics for RVD treatment is further emphasized by these findings.
format article
author Brandon Jacobs
Nicholas Palmer
Trupti Shetty
Helen Dimaras
Amir Hajrasouliha
Denis Jusufbegovic
Timothy W. Corson
author_facet Brandon Jacobs
Nicholas Palmer
Trupti Shetty
Helen Dimaras
Amir Hajrasouliha
Denis Jusufbegovic
Timothy W. Corson
author_sort Brandon Jacobs
title Patient preferences in retinal drug delivery
title_short Patient preferences in retinal drug delivery
title_full Patient preferences in retinal drug delivery
title_fullStr Patient preferences in retinal drug delivery
title_full_unstemmed Patient preferences in retinal drug delivery
title_sort patient preferences in retinal drug delivery
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec8
work_keys_str_mv AT brandonjacobs patientpreferencesinretinaldrugdelivery
AT nicholaspalmer patientpreferencesinretinaldrugdelivery
AT truptishetty patientpreferencesinretinaldrugdelivery
AT helendimaras patientpreferencesinretinaldrugdelivery
AT amirhajrasouliha patientpreferencesinretinaldrugdelivery
AT denisjusufbegovic patientpreferencesinretinaldrugdelivery
AT timothywcorson patientpreferencesinretinaldrugdelivery
_version_ 1718378486811328512